<code id='4FBF41D8CC'></code><style id='4FBF41D8CC'></style>
    • <acronym id='4FBF41D8CC'></acronym>
      <center id='4FBF41D8CC'><center id='4FBF41D8CC'><tfoot id='4FBF41D8CC'></tfoot></center><abbr id='4FBF41D8CC'><dir id='4FBF41D8CC'><tfoot id='4FBF41D8CC'></tfoot><noframes id='4FBF41D8CC'>

    • <optgroup id='4FBF41D8CC'><strike id='4FBF41D8CC'><sup id='4FBF41D8CC'></sup></strike><code id='4FBF41D8CC'></code></optgroup>
        1. <b id='4FBF41D8CC'><label id='4FBF41D8CC'><select id='4FBF41D8CC'><dt id='4FBF41D8CC'><span id='4FBF41D8CC'></span></dt></select></label></b><u id='4FBF41D8CC'></u>
          <i id='4FBF41D8CC'><strike id='4FBF41D8CC'><tt id='4FBF41D8CC'><pre id='4FBF41D8CC'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:369
          Blue Cross Blue Shield website seen on several laptop screens. -- health business coverage from STAT
          Adobe

          A program that undergirds the Affordable Care Act’s health insurance marketplaces continues to bolster the balance sheets of large Blue Cross Blue Shield companies, according to a STAT analysis of new federal data.

          Conversely, that same program — called “risk adjustment” — has created substantial financial burdens for startup insurers including Bright Health Group, which has now exited all health insurance markets, and Friday Health Plans, which has shut down.

          advertisement

          More than two dozen BCBS insurers are projected to collect more than $4.7 billion from competing insurers on the ACA marketplaces, according to the analysis. The biggest amounts are concentrated among a few dominant Blues conglomerates.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Vertex non
          Vertex non

          JOSEPHPREZIOSO/AFPviaGettyImagesLate-stagetrialresultsforapainmedicationdevelopedbyVertexPharmaceuti

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

          InsitroCEOandfounderDaphneKollerNeilsonBarnard/GettyImagesforTheNewYorkTimesSANFRANCISCO—Ittookonlya